Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Bribery Act enters into force; companies urged to implement anti-corruption programmes

This article was originally published in RAJ Devices

Executive Summary

The UK Bribery Act comes into force today, marking the start of a new era in enforcement1,2.

You may also be interested in...



Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection

Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved  for treating this aggressive and difficult-to-treat form of breast cancer.

Australia Fast-Tracks Over 40 COVID-19 Tests; Concern Emerges Over Sensitivity Claims

The country's Therapeutic Goods Administration has explained how sponsors can apply for expedited approval of tests for COVID-19 and what special conditions apply. Meanwhile, post-market reviews of two approved serology-based COVID-19 point-of-care tests suggest they are not as sensitive as their manufacturers had claimed.

EMA’s Rasi: Approval Decision For Remdesivir May Come ‘Very Soon’

Speaking at a high-level European Parliament committee meeting today about COVID-19, the European Medicines Agency’s executive director indicated that Gilead would be submitting a conditional marketing authorization application for remdesivir in the EU.

UsernamePublicRestriction

Register

AP000801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel